Condition (MeSH)
Scleroderma, Limited
ClinicalTrials.gov lists 12 trials for Scleroderma, Limited or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 12 trials are tagged with Scleroderma, Limited itself; the rest are tagged with a narrower condition beneath it.
When did Scleroderma, Limited trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2009 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Scleroderma, Limited trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 2 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 2 |
How many Scleroderma, Limited trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 5 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Scleroderma, Limited trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Cumberland Pharmaceuticals | 1 |
| Galderma R&D | 1 |
| Gilead Sciences | 1 |
| Medtronic Spinal and Biologics | 1 |
| United Therapeutics | 1 |
Which drugs are being tested for Scleroderma, Limited? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nitric Oxide | 1 |
| SILDENAFIL | 1 |
| Ifetroban | 1 |
| Nemolizumab | 1 |
| Treprostinil | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| hyaluronidase injected intradermally | 1 |
| Mofetil Mycophenolate | 1 |
| Lidocaine 2% without vessel constrictor | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Scleroderma, Limited trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 2 | 2 |
| Pneumonia | 2 | 1 |
| Pneumothorax | 2 | 1 |
| Pseudarthrosis | 2 | 1 |
| Vomiting | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Scleroderma, Limited? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Impact of concomitant obstructive sleep apnea on pulmonary involvement and main pulmonary artery diameter in adults with scleroderma. | Sleep & breathing = Schlaf & Atmung | 2021 | Yes |
| Exploring the feasibility of an exercise programme including aerobic and resistance training in people with limited cutaneous systemic sclerosis. | Clinical rheumatology | 2020 | Yes |
| The evaluation of a home-based program for hands in patients with systemic sclerosis. | Journal of hand therapy : official journal of the American Society of Hand Therapists | 2019 | Yes |
| Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report. | Scandinavian journal of rheumatology | 2019 | Yes |
| Exploring the microcirculatory effects of an exercise programme including aerobic and resistance training in people with limited cutaneous systemic sclerosis. | Microvascular research | 2019 | Yes |
Showing 5 of 17 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.